CN1925847A - 增强欧司哌米芬生物利用度的方法 - Google Patents

增强欧司哌米芬生物利用度的方法 Download PDF

Info

Publication number
CN1925847A
CN1925847A CNA200580004550XA CN200580004550A CN1925847A CN 1925847 A CN1925847 A CN 1925847A CN A200580004550X A CNA200580004550X A CN A200580004550XA CN 200580004550 A CN200580004550 A CN 200580004550A CN 1925847 A CN1925847 A CN 1925847A
Authority
CN
China
Prior art keywords
ospemifene
food intake
chemical compound
food
purposes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA200580004550XA
Other languages
English (en)
Chinese (zh)
Inventor
M·安蒂拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hormos Medical Ltd
Original Assignee
Hormos Medical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34837941&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1925847(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hormos Medical Ltd filed Critical Hormos Medical Ltd
Publication of CN1925847A publication Critical patent/CN1925847A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CNA200580004550XA 2004-02-13 2005-01-14 增强欧司哌米芬生物利用度的方法 Pending CN1925847A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/777,211 2004-02-13
US10/777,211 US8236861B2 (en) 2004-02-13 2004-02-13 Method for enhancing the bioavailablity of ospemifene

Publications (1)

Publication Number Publication Date
CN1925847A true CN1925847A (zh) 2007-03-07

Family

ID=34837941

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA200580004550XA Pending CN1925847A (zh) 2004-02-13 2005-01-14 增强欧司哌米芬生物利用度的方法

Country Status (23)

Country Link
US (5) US8236861B2 (enExample)
EP (1) EP1713458B1 (enExample)
JP (2) JP5577011B2 (enExample)
CN (1) CN1925847A (enExample)
AT (1) ATE387910T1 (enExample)
AU (1) AU2005211958B2 (enExample)
BE (1) BE2015C033I2 (enExample)
BR (1) BRPI0507661A (enExample)
CA (1) CA2556089C (enExample)
CY (2) CY1111014T1 (enExample)
DE (1) DE602005005165T2 (enExample)
DK (1) DK1713458T5 (enExample)
ES (1) ES2302177T3 (enExample)
FR (1) FR15C0041I2 (enExample)
HU (1) HUS1500030I1 (enExample)
LT (1) LTC1713458I2 (enExample)
LU (1) LU92736I2 (enExample)
MX (1) MXPA06009274A (enExample)
NO (2) NO337656B1 (enExample)
PL (1) PL1713458T3 (enExample)
PT (1) PT1713458E (enExample)
RU (1) RU2385716C2 (enExample)
WO (1) WO2005077350A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103739456A (zh) * 2013-12-03 2014-04-23 镇江圣安医药有限公司 2-（对-（（z-4-氯-1,2-二苯基-1-丁烯基）苯氧基）乙醇的新型衍生物及其应用

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8236861B2 (en) 2004-02-13 2012-08-07 Hormos Medical Corporation Method for enhancing the bioavailablity of ospemifene
US8642079B2 (en) * 2004-02-23 2014-02-04 Hormos Medical Corporation Solid formulations of ospemifene
ES2392344T3 (es) 2004-05-04 2012-12-07 Hormos Medical Ltd. Formulaciones orales líquidas de ospemifeno
BRPI0618510A2 (pt) * 2005-11-09 2011-09-06 Hormos Medical Ltd formulação medicamentosa lìquida ou semi-sólida
US8637706B2 (en) 2005-11-28 2014-01-28 Gtx, Inc. Nuclear receptor binding agents
US8158828B2 (en) * 2005-11-28 2012-04-17 Gtx, Inc. Nuclear receptor binding agents
US8546451B2 (en) * 2005-11-28 2013-10-01 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US9409856B2 (en) 2005-11-28 2016-08-09 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
CA2824517A1 (en) * 2005-11-28 2007-05-31 Gtx, Inc. Nuclear receptor binding agents
WO2008099060A2 (en) * 2007-02-14 2008-08-21 Hormos Medical Ltd Methods for the preparation of fispemifene from ospemifene
ES2590262T3 (es) * 2007-02-14 2016-11-21 Hormos Medical Ltd. Método para la preparación de derivados de trifenilbuteno con valor terapéutico
US9427418B2 (en) 2009-02-23 2016-08-30 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US9624161B2 (en) 2009-02-23 2017-04-18 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US9321712B2 (en) 2012-10-19 2016-04-26 Fermion Oy Process for the preparation of ospemifene
GR1009542B (el) 2018-04-25 2019-06-07 Φαρματεν Α.Β.Ε.Ε. Καψουλα μαλακης γελης που περιλαμβανει εναν εκλεκτικο ρυθμιστη οιστρογονικων υποδοχεων
MA52569B1 (fr) 2018-05-11 2023-11-30 Xenon Pharmaceuticals Inc Méthodes pour améliorer la biodisponibilité et l'exposition d'un activateur de canal potassique voltage-dépendant
TWI886158B (zh) 2019-10-10 2025-06-11 加拿大商再諾製藥公司 選擇性鉀通道調節劑之固態晶型
CA3155812A1 (en) 2019-11-08 2021-05-14 Cynthia Louise HARDEN Methods of treating depressive disorders
TW202245744A (zh) 2021-02-09 2022-12-01 加拿大商再諾製藥公司 治療失樂症之方法及用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9007052D0 (en) * 1990-03-29 1990-05-30 Skua Investments Ltd Pharmaceutical formulations
GB9207437D0 (en) 1992-04-03 1992-05-20 Orion Yhtymae Oy Topical administration of toremifene and its metabolites
GB9418067D0 (en) 1994-09-07 1994-10-26 Orion Yhtymae Oy Triphenylethylenes for the prevention and treatment of osteoporosis
GB9604577D0 (en) 1996-03-04 1996-05-01 Orion Yhtymae Oy Serum cholesterol lowering agent
ATE315033T1 (de) * 1998-08-07 2006-02-15 Chiron Corp Subtituierte isoxazole derivate als estrogen rezeptor modulatore
US6219674B1 (en) 1999-11-24 2001-04-17 Classen Immunotherapies, Inc. System for creating and managing proprietary product data
US6245819B1 (en) 2000-07-21 2001-06-12 Hormos Medical Oy, Ltd. Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause
US6653639B1 (en) * 2000-10-17 2003-11-25 Nikon Corporation Chuck for mounting reticle to a reticle stage
WO2002069254A2 (en) 2001-02-22 2002-09-06 Classen Immunotherapies, Inc. Improved algorithms and methods for products safety
FR2826811B1 (fr) 2001-06-27 2003-11-07 France Telecom Procede d'authentification cryptographique
NZ536118A (en) 2002-06-06 2007-08-31 Hormos Medical Ltd Method for the inhibition of urogenital atrophy or for treatment or prevention of urogenital atrophy-related symptoms in women
US8236861B2 (en) 2004-02-13 2012-08-07 Hormos Medical Corporation Method for enhancing the bioavailablity of ospemifene
US20050187302A1 (en) 2004-02-23 2005-08-25 Hormos Medical Corporation Method for treatment or prevention of osteoporosis in individuals with high bone turnover
US8642079B2 (en) 2004-02-23 2014-02-04 Hormos Medical Corporation Solid formulations of ospemifene
ES2392344T3 (es) 2004-05-04 2012-12-07 Hormos Medical Ltd. Formulaciones orales líquidas de ospemifeno
US20060293294A1 (en) 2004-09-03 2006-12-28 Hormos Medical Corporation Method for treatment or prevention of androgen deficiency
KR100665758B1 (ko) * 2005-09-15 2007-01-09 제일모직주식회사 반사방지성을 갖는 하드마스크 조성물

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103739456A (zh) * 2013-12-03 2014-04-23 镇江圣安医药有限公司 2-（对-（（z-4-氯-1,2-二苯基-1-丁烯基）苯氧基）乙醇的新型衍生物及其应用

Also Published As

Publication number Publication date
EP1713458A1 (en) 2006-10-25
US8772353B2 (en) 2014-07-08
US9855224B2 (en) 2018-01-02
EP1713458B1 (en) 2008-03-05
LU92736I2 (fr) 2015-08-10
BRPI0507661A (pt) 2007-07-17
DE602005005165T2 (de) 2009-04-30
US20120270952A1 (en) 2012-10-25
ATE387910T1 (de) 2008-03-15
DK1713458T3 (da) 2008-07-07
WO2005077350A1 (en) 2005-08-25
DK1713458T5 (da) 2008-09-29
HUS1500030I1 (hu) 2015-08-28
PT1713458E (pt) 2008-05-07
CY2015027I2 (el) 2016-04-13
DE602005005165D1 (de) 2008-04-17
BE2015C033I2 (enExample) 2024-08-08
US20140303259A1 (en) 2014-10-09
PL1713458T3 (pl) 2008-08-29
RU2006132719A (ru) 2008-03-20
LTPA2015023I1 (lt) 2015-08-25
NO337656B1 (no) 2016-05-23
CY2015027I1 (el) 2016-04-13
JP6023119B2 (ja) 2016-11-09
JP5577011B2 (ja) 2014-08-20
CA2556089A1 (en) 2005-08-25
CY1111014T1 (el) 2015-06-11
US20130324614A1 (en) 2013-12-05
ES2302177T3 (es) 2008-07-01
NO339190B1 (no) 2016-11-14
NO20063960L (no) 2006-11-03
US20050182143A1 (en) 2005-08-18
US8470890B2 (en) 2013-06-25
MXPA06009274A (es) 2007-04-16
FR15C0041I2 (fr) 2015-11-13
US20160101065A1 (en) 2016-04-14
US8236861B2 (en) 2012-08-07
AU2005211958B2 (en) 2010-11-25
LTC1713458I2 (lt) 2017-06-26
RU2385716C2 (ru) 2010-04-10
JP2007522190A (ja) 2007-08-09
NO20151603L (no) 2006-11-03
AU2005211958A1 (en) 2005-08-25
JP2014141533A (ja) 2014-08-07
US9241915B2 (en) 2016-01-26
CA2556089C (en) 2013-04-02
FR15C0041I1 (enExample) 2015-07-17

Similar Documents

Publication Publication Date Title
JP6023119B2 (ja) オスペミフェンの生物学的利用能を高める方法
US11400072B2 (en) Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
EP3054940B1 (en) Compositions and methods for treating non-alcoholic steatohepatitis
JPH0825875B2 (ja) ３―グアニジノプロピオン酸の代謝障害の治療用組成物
NO329954B1 (no) Anvendelse av (deaminohydroksy)toremifen for fremstilling av en farmasoytisk blanding
AU2017206480A1 (en) Composition, containing Loganin or a derivative thereof as an active ingredient for preventing, remedying, or treating female climacteric syndrome
WO2019220335A1 (en) Compositions for use in the treatment of obesity
CN1950071A (zh) ospemifene的新口服制剂
KR101304536B1 (ko) 4-하이드록시 타목시펜 유사체 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 간질환의 치료 또는 예방용 조성물
KR20170118787A (ko) 노년 남성에서 정신적, 신체적, 및 성적 병태를 향상시키기 위한 호로파 추출물의 용도
KR20070022220A (ko) 오스페미펜의 생물학적 이용가능성 강화방법
CN118178661A (zh) 一种治疗非酒精性脂肪肝的药物组合物
EA042686B1 (ru) Способ лечения неалкогольного стеатогепатита

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication